NCT05995028View on ClinicalTrials.gov

Universal 4SCAR7U Targeting CD7-positive Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
T-cell Acute Lymphoblastic LeukemiaT-cell Acute Lymphoblastic LymphomaAcute Myeloid LeukemiaNK Cell Lymphoma
Interventions
BIOLOGICAL

Universal CD7-specific CAR gene-engineered T cells

Infusion of 4SCAR7U T cells

Trial Locations (1)

518000

RECRUITING

Shenzhen Geno-immune Medical Institute, Shenzhen

All Listed Sponsors
lead

Shenzhen Geno-Immune Medical Institute

OTHER